The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo

Investor logo

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Science. Official publication website can be found on muni.cz.
Authors

BOUCHAL Pavel JARKOVSKÝ Jiří HRAZDILOVÁ Kristýna DVOŘÁKOVÁ Monika STRUHÁROVÁ Iva HERNYCHOVÁ Lenka DAMBORSKÝ Jiří SOVA Petr VOJTĚŠEK Bořivoj

Year of publication 2011
Type Article in Periodical
Magazine / Source Proteome Science
MU Faculty or unit

Faculty of Science

Citation
Web http://www.proteomesci.com/content/9/1/68
Doi http://dx.doi.org/10.1186/1477-5956-9-68
Field Biochemistry
Keywords (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum (IV) (LA-12); plasma retinol-binding protein 4; RBP4; cisplatin; adamantylamine; proteomics
Attached files
Description Background: The initial pharmacokinetic study of a new anticancer agent (OC-6-43)-bis(acetato)(1-adamantylamine) amminedichloroplatinum (IV) (LA-12) was complemented by proteomic screening of rat plasma. The objective of the study was to identify new LA-12 target proteins that serve as markers of LA-12 treatment, response and therapy monitoring. Methods: Proteomic profiles were measured by surface-enhanced laser desorption-ionization time-of-flight mass spectrometry (SELDI-TOF MS) in 72 samples of rat plasma randomized according to LA-12 dose and time from administration. Correlation of 92 peak clusters with platinum concentration was evaluated using Spearman correlation analysis. Results: We identified Retinol-binding protein 4 (RBP4) whose level correlated with LA-12 level in treated rats. Similar results were observed in randomly selected patients involved in Phase I clinical trials. Conclusions: RBP4 induction is in agreement with known RBP4 regulation by amantadine and cisplatin.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info